Table 5. Comparison of clinical characteristics between LDL-C ≥ 70 vs. LDL-C ＜70 mg/dl at 2 months among patients who had not taken any lipid-lowering medications at baseline.
| LDL-C ≥70 mg/dl at 2 months (n= 102) | LDL-C ＜70 mg/dl at 2 months (n= 76) | p value | |
|---|---|---|---|
| Age, years | 68±12 | 70±12 | 0.40 |
| Women, n (%) | 20 (19.6) | 11 (14.5) | 0.43 |
| BMI, kg/m2 | 24.0±4.4 | 23.7±3.5 | 0.68 |
| History of diabetes mellitus, n (%) | 44 (43.1) | 30 (39.5) | 0.65 |
| History of dyslipidemia, n (%) | 71 (69.6) | 56 (73.7) | 0.62 |
| History of hypertension, n (%) | 76 (74.5) | 58 (76.3) | 0.86 |
| History of COPD, n (%) | 7 (6.9) | 4 (5.3) | 0.76 |
| Use of anti-hypertension drugs, n (%) | 24 (23.5) | 15 (19.7) | 0.59 |
| Baseline eGFR, ml/min/1.73 m2 | 61.3±24.2 | 63.6±23.0 | 0.52 |
| Baseline LDL-C, mg/dl | 126±38 | 110±32 | ＜0.01† |
| Baseline HDL-C, mg/dl | 44±11 | 45±12 | 0.48 |
| Baseline TG, mg/dl | 118 (69 to 198) | 121 (74 to 223) | 0.59 |
| Baseline HbA1c, % | 6.1 (5.7 to 6.7) | 6.0 (5.7 to 6.6) | 0.58 |
| Baseline uric acid, mg/dl | 6.3±1.6 | 5.8±1.7 | 0.09 |
| Baseline high-sensitive C-reactive protein, mg/dl | 0.2 (0.1-0.4) | 0.2 (0.1-0.4) | 0.83 |
| Baseline use of lipid-lowering drugs, n (%) | 0 (0.0) | 0 (0.0) | NA |
| Baseline use of antidiabetic drugs | 9 (8.8) | 6 (7.9) | 1.00 |
| Use of lipid-lowering drugs during M0 to M2, n (%) | 83 (81.4) | 69 (90.8) | 0.09 |
| Cumulative DDD of statins during M0 to M2 | 31.3±23.6 | 40.5±22.8 | ＜0.01 |
| Cumulative DDD of standard statins during M0 to M2 | 0.3±2.2 | 0.3±1.8 | 0.98 |
| Cumulative DDD of strong statins during M0 to M2 | 31.0±23.9 | 40.2±23.2 | ＜0.05 |
| Cumulative DDD of fibrates during M0 to M2 | 0.0±0.0 | 0.0±0.0 | NA |
| Cumulative DDD of ezetimibe during M0 to M2 | 1.8±9.4 | 4.1±13.1 | 0.18 |
| Cumulative DDD of other lipid-lowering drugs during M0 to M2 | 0.0±0.4 | 0.0±0.0 | 0.32 |
Data are expressed as the mean±SD for unskewed variables, median (interquartile range) for skewed variables, and counts (%) for countable variables. BMI = body mass index, COPD = chronic obstructive pulmonary disease, DDD = defined daily dose, eGFR = estimated glomerular filtration rate, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, TG = triglyceride. M0 = baseline, M2= visit point two months after the baseline. NA = not available.